Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 11, 2007, Pages 4191-4195

  Bogdanovich, Tatiana ^a   Clark, Catherine ^a   Kosowska Shick, Klaudia ^a   Dewasse, Bonifacio ^a   McGhee, Pamela ^a   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; BACTERIAL PROTEIN; CG400549; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LEVOFLOXACIN; LINEZOLID; METICILLIN; PROTEIN FABI; PROTEIN FABI INHIBITOR; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; DRUG SENSITIVITY; MINIMUM INHIBITORY CONCENTRATION; MULTISTEP ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SINGLE PASSAGE SELECTION TEST; STAPHYLOCOCCUS AUREUS; TECHNIQUE;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ENZYME INHIBITORS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; OXAZOLIDINONES; PYRIDINES; STAPHYLOCOCCUS AUREUS; THIOPHENES; VIRGINIAMYCIN;

EID: 35848930171     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00550-07     Document Type: Article

References (22)

1. Baldock, C., J. B. Rafferty, S. E. Sedelnikova, P. J. Baker, A. R. Stuitje, A. R. Slabas, T. R. Hawkes, and D. W. Rice. 1996. A mechanism of drug action revealed by structural studies of enoyl reductase. Science 274:2107-2110.
2. Bannerman, T. L., G. A. Hancock, F. C. Tenover, and J. M. Miller. 1995. Pulsed-field electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus. J. Clin. Microbiol. 33:551-555.
3. Bartley, J. 2002. First case of VRSA identified in Michigan. Infect. Control Hosp. Epidemiol. 23:480.
4. Begier, E. M., K. Frenette, B. L. Barrett, P. Mshar, S. Petit, D. J. Boxrud, K. Watkins-Colwell, S. Wheeler, E. A. Cebelinski, A. Glennen, D. Nguyen, J. L. Hadler, and the Connecticut Bioterrorism Field Epidemiology Response Team. 2004. A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns. Clin. Infect. Dis. 39:1446-1453.
5. Bergler, H., S. Fuchsbichler, G. Högenauer, and F. Turnowsky. 1996. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA. Eur. J. Biochem. 242:689-694.
6. Bogdanovich, T., D. Esel, L. Kelly, B. Bozdogan, K. Credito, G. Lin, K. Smith, L. Ednie, D. Hoellman, and P. C. Appelbaum. 2005. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents. Antimicrob. Agents Chemother. 49:3325-3333.
7. Boyle-Vavra, S., S. K. Berke, J. C. Lee, and R. S. Daum. 2000. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob. Agents Chemother. 44:272-277.
8. Centers for Disease Control and Prevention. 2004. Vancomycin-resistant Staphylococcus aureus - New York, 2004. Morb. Mortal. Wkly. Rep. 53:322-323.
9. Centers for Disease Control and Prevention. 1999. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999. Morb. Mortal. Wkly. Rep. 48:707-710.
10. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Fergie, J. E., and K. Purcell. 2001. Community-acquired methicillin-resistant Staphylococcus aureus infections in south Texas children. Pediatr. Infect. Dis. J. 20:860-863.
12. Heath, R. J., Y.-T. Yu, M. A. Shapiro, E. Olson, and C. O. Rock. 1998. Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis. J. Biol. Chem. 273:30316-30320.
13. Kaatz, G. W., T. S. Lundstrom, and S. M. Seo. 2006. Mechanisms of daptomycin resistance in Staphylococcus aureus. Int. J. Antimicrob. Agents 28:280-287.
14. Kazakova, S. V., J. C. Hageman, M. Matava, A. Srinivasan, L. Phelan, B. Garfinkel, T. Boo, S. McAllister, J. Anderson, B. Jensen, D. Dodson, D. Lonsway, L. K. McDougal, M. Arduino, V. J. Fraser, G. Killgore, F. C. Tenover, S. Cody, and D. B. Jernigan. 2005. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N. Engl. J. Med. 352:468-475.
15. Kosowska-Shick, K., M. Roos, H. Labischinski, C. Whitener, K. Julian, and P. C. Appelbaum. 2006. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., abstr. C1-685.
16. McDougal, L. K., C. D. Steward, G. E. Killgore, J. M. Chaitram, S. K. McAllister, and F. C. Tenover. 2003. Pulsed-field electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J. Clin. Microbiol. 41:5113-5120.
17. McMurry, L., M. Oethinger, and S. B. Levy. 1998. Triclosan targets lipid synthesis. Nature 394:531-532.
18. Naimi, T. S., K. H. LeDell, K. Como-Sabetti, S. M. Borchardt, D. J. Boxrud, J. Etienne, S. K. Johnson, F. Vandenesch, S. Fridkin, C. O'Boyle, R. N. Danila, and R. Lynfield. 2003. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290:2976-2984.
19. Payne, D. J., W. H. Miller, V. Berry, J. Brosky, W. J. Burgess, E. Chen, W. E. DeWolf, Jr., A. P. Fosberry, R. Greenwood, M. S. Head, D. A. Heerding, C. A. Janson, D. D. Jaworski, P. M. Keller, P. J. Manley, T. D. Moore, K. A. Newlander, S. Pearson, B. J. Polizzi, X. Qiu, S. F. Rittenhouse, C. Slater-Radosti, K. L. Salyers, M. A. Seefeld, M. G. Smyth, D. T. Takata, I. N. Uzinskas, K. Vaidya, N. G. Wallis, S. B. Winram, C. C. K. Yuan, and W. F. Huffman. 2002. Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob. Agents Chemother. 46:3118-3124.
20. Slater-Radosti, C., G. Van Aller, R. Greenwood, R. O. Nicholas, P. Keller, W. E. DeWolf, F. Fan, D. J. Payne, and D. D. Jaworski. 2001. Biochemical and genetic characterisation of the action of triclosan on Staphylococcus aureus. J. Antimicrob. Chemother. 48:1-6.
21. Tenover, F. C., M. V. Lancaster, B. C. Hill, C. D. Steward, S. A. Stocker, G. A. Hancock, C. M. O'Hara, N. C. Clark, and K. Hiramatsu. 1998. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J. Clin. Microbiol. 36:1020-1027.
22. Tenover, F. C., L. M. Weigel, P. C. Appelbaum, L. K. McDougal, J. Chaitram, S. McAllister, N. Clark, G. Killgore, C. M. O'Hara, L. Jevitt, J. B. Patel, and B. Bozdogan. 2004. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob. Agents Chemother. 48:275-280.